{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Mild+Cognitive+Impairment+%28MCI%29+Due+to+Alzheimer%27s+Disease&page=2",
    "query": {
      "condition": "Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Mild+Cognitive+Impairment+%28MCI%29+Due+to+Alzheimer%27s+Disease&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-26T12:47:47.685Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07224607",
      "title": "Transcranial Photobiomodulation (tPBM) in Alzheimer's Disease Study",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "Photobiomodulation",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Cedars-Sinai Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "55 Years to 89 Years"
      },
      "enrollment_count": 45,
      "start_date": "2025-12-25",
      "completion_date": "2026-10",
      "has_results": false,
      "last_update_posted_date": "2025-11-19",
      "last_synced_at": "2026-06-26T12:47:47.685Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07224607"
    },
    {
      "nct_id": "NCT06489548",
      "title": "Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dementia",
        "Alzheimers Disease",
        "Mild Cognitive Impairment Due to Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "Foralumab TZLS-401 50 µg",
          "type": "DRUG"
        },
        {
          "name": "Foralumab TZLS-401 100 µg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "60 Years to 85 Years"
      },
      "enrollment_count": 16,
      "start_date": "2025-09-16",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-02-12",
      "last_synced_at": "2026-06-26T12:47:47.685Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06489548"
    },
    {
      "nct_id": "NCT07553338",
      "title": "Safety Assessment of Leronlimab and Its Effect on Brain Inflammation in Alzheimer's Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease",
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "Leronlimab (700mg)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Weill Medical College of Cornell University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2026-04-30",
      "completion_date": "2027-11",
      "has_results": false,
      "last_update_posted_date": "2026-05-22",
      "last_synced_at": "2026-06-26T12:47:47.685Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07553338"
    },
    {
      "nct_id": "NCT01931566",
      "title": "Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Mild Cognitive Impairment Due to Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "Pioglitazone",
          "type": "DRUG"
        },
        {
          "name": "Pioglitazone placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": "83 Years",
        "sex": "ALL",
        "summary": "65 Years to 83 Years"
      },
      "enrollment_count": 3494,
      "start_date": "2013-08-01",
      "completion_date": "2018-09-06",
      "has_results": true,
      "last_update_posted_date": "2019-09-16",
      "last_synced_at": "2026-06-26T12:47:47.685Z",
      "location_count": 34,
      "location_summary": "Phoenix, Arizona • Sun City, Arizona • Long Beach, California + 31 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01931566"
    },
    {
      "nct_id": "NCT02414282",
      "title": "F 18 T807 Tau PET Imaging of Progressive Posterior Cortical Dysfunction (IND 123119, Protocol E)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Alzheimer Disease",
        "Progressive Posterior Cortical Dysfunction (PPCD)"
      ],
      "interventions": [
        {
          "name": "F 18 T807",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tammie L. S. Benzinger, MD, PhD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "45 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2015-03",
      "completion_date": "2020-10-20",
      "has_results": false,
      "last_update_posted_date": "2021-01-19",
      "last_synced_at": "2026-06-26T12:47:47.685Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02414282"
    },
    {
      "nct_id": "NCT04795466",
      "title": "Study of the Efficacy and Safety of Various Anti-inflammatory Agents in Participants With Mild Cognitive Impairment or Mild Alzheimer's Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Mild Cognitive Impairment",
        "Alzheimer Disease"
      ],
      "interventions": [
        {
          "name": "Canakinumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "45 Years to 90 Years"
      },
      "enrollment_count": 34,
      "start_date": "2021-10-28",
      "completion_date": "2024-03-07",
      "has_results": true,
      "last_update_posted_date": "2025-10-16",
      "last_synced_at": "2026-06-26T12:47:47.685Z",
      "location_count": 2,
      "location_summary": "Charlestown, Massachusetts • Stony Brook, New York",
      "locations": [
        {
          "city": "Charlestown",
          "state": "Massachusetts"
        },
        {
          "city": "Stony Brook",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04795466"
    },
    {
      "nct_id": "NCT03019536",
      "title": "A Study of LY3303560 in Participants With Mild Cognitive Impairment or Alzheimer's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Alzheimer Disease"
      ],
      "interventions": [
        {
          "name": "LY3303560 - IV",
          "type": "DRUG"
        },
        {
          "name": "Placebo - IV",
          "type": "DRUG"
        },
        {
          "name": "Florbetapir F 18",
          "type": "DRUG"
        },
        {
          "name": "Flortaucipir F18",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2017-01-31",
      "completion_date": "2019-06-05",
      "has_results": true,
      "last_update_posted_date": "2023-10-10",
      "last_synced_at": "2026-06-26T12:47:47.685Z",
      "location_count": 5,
      "location_summary": "Melbourne, Florida • Orlando, Florida • Port Orange, Florida + 2 more",
      "locations": [
        {
          "city": "Melbourne",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Port Orange",
          "state": "Florida"
        },
        {
          "city": "The Villages",
          "state": "Florida"
        },
        {
          "city": "Princeton",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03019536"
    },
    {
      "nct_id": "NCT06247345",
      "title": "A Phase Ia/Ib, First-in-human (FIH) Study for Safety, Tolerability, Pharmacokinetics (PK), and Clinical Activity Evaluation of ADEL-Y01",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Alzheimer Disease"
      ],
      "interventions": [
        {
          "name": "ADEL-Y01 - healty participants",
          "type": "DRUG"
        },
        {
          "name": "Placebo - Healthy Participants",
          "type": "DRUG"
        },
        {
          "name": "ADEL-Y01 - MCI/AD",
          "type": "DRUG"
        },
        {
          "name": "Placebo - MCI/AD",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alzheimer's Disease Expert Lab (ADEL), Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 42,
      "start_date": "2024-02-06",
      "completion_date": "2026-01-07",
      "has_results": false,
      "last_update_posted_date": "2026-04-30",
      "last_synced_at": "2026-06-26T12:47:47.685Z",
      "location_count": 6,
      "location_summary": "Anaheim, California • Lady Lake, Florida • Maitland, Florida + 3 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Lady Lake",
          "state": "Florida"
        },
        {
          "city": "Maitland",
          "state": "Florida"
        },
        {
          "city": "Palmetto Bay",
          "state": "Florida"
        },
        {
          "city": "Decatur",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06247345"
    },
    {
      "nct_id": "NCT01837641",
      "title": "A Study of LY3002813 in Participants With Alzheimer's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Alzheimer Disease"
      ],
      "interventions": [
        {
          "name": "LY3002813-IV",
          "type": "BIOLOGICAL"
        },
        {
          "name": "LY3002813-SC",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo-IV",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 63,
      "start_date": "2013-05-03",
      "completion_date": "2016-08-24",
      "has_results": true,
      "last_update_posted_date": "2024-10-04",
      "last_synced_at": "2026-06-26T12:47:47.685Z",
      "location_count": 4,
      "location_summary": "Long Beach, California • Orlando, Florida • Atlanta, Georgia + 1 more",
      "locations": [
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01837641"
    },
    {
      "nct_id": "NCT05399888",
      "title": "A Study to Learn About the Safety of BIIB080 Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Mild Cognitive Impairment Due to Alzheimer's Disease",
        "Alzheimer's Disease Dementia"
      ],
      "interventions": [
        {
          "name": "BIIB080",
          "type": "DRUG"
        },
        {
          "name": "BIIB080-matching placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "50 Years to 80 Years"
      },
      "enrollment_count": 416,
      "start_date": "2022-08-24",
      "completion_date": "2028-06-06",
      "has_results": false,
      "last_update_posted_date": "2026-06-05",
      "last_synced_at": "2026-06-26T12:47:47.685Z",
      "location_count": 36,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 30 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05399888"
    }
  ]
}